The Effects of Serum ANGPTL8/betatrophin on the Risk of Developing the Metabolic Syndrome – A Prospective Study

• Published in: Scientific reports Vol. 6; no. 1; p. 28431
• Main Authors: Wang, Haoyu, Lai, Yaxin, Han, Cheng, Liu, Aihua, Fan, Chenling, Wang, Hong, Zhang, Hongmei, Ding, Shuangning, Teng, Weiping, Shan, Zhongyan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.06.2016; Nature Publishing Group
• Subjects: 692/163/2743/2037; 692/308/174; 692/53/2423; 692/699/2743/2037; Adipose tissue; Blood pressure; Body mass index; Cholesterol; Endocrinology; Females; Glucose; High density lipoprotein; Homeostasis; Humanities and Social Sciences; Insulin resistance; Lipoproteins; Males; Metabolic disorders; Metabolic syndrome; multidisciplinary; Plasma; Science; Triglycerides; China
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep28431

ANGPTL8/betatrophin is a recently discovered hormone, which mainly synthesized and secreted by liver and adipose tissue, playing a critical role in pancreatic beta cell proliferation. Previous studies have suggested that serum ANGPTL8/betatrophin levels are associated with obesity and diabetes mellitus. Here, we evaluated the prospective association between ANGPTL8/betatrophin and the metabolic syndrome from a community-based cohort of 153 adults without metabolic syndrome. After 3.5-year follow-up, we observed an inverse correlation between the baseline ANGPTL8/betatrophin levels and the incidence of metabolic syndrome, even after multivariate adjustments. In receiver operating characteristic analysis, the area underneath the curve for ANGPTL8/betatrophin was 0.70 in males and 0.86 in females and the optimal cut-off values were 23.9 ng/mL and 31.1 ng/mL, respectively. This article suggests that ANGPTL8/betatrophin might be useful in predicting newly-onset metabolic syndrome and its progression in clinical setting.